Back to overview

Neumirna at the EVF global accelerator course

In 2021, NEUmiRNA was selected and awarded by the US Epilepsy Foundation as being a promising start-up to advance new treatments for people with epilepsy in the EVF global accelerator course for start-up companies.
Funding

Related topics

Funding
Awards
12.6.2025
Neumirna Receives 2024 CURE Epilepsy Catalyst Award
$250,000 in funding to support biomarker research and development of RNA therapy for drug-resistant epilepsy
Read full article
Awards
Funding
11.6.2025
Neumirna Receives 2025 Epilepsy Foundation Shark Tank Investment
$200,000 award supports Neumirna’s RNA-based approach to innovation in epilepsy treatment
Read full article
Funding
27.3.2025
Neumirna awarded a Eureka Network EUROSTARS grant of 1.65M€ in collaboration with Motac Neuroscience Ltd, the Université de Bordeaux and the Center for RNA Medicine!
This grant will enable us to develop innovative RNA therapies which could revolutionize the treatment of Parkinson's Disease.
Read full article